Although CD30 testing is an established tool in the diagnostic workup of lymphomas, it is also emerging as a predictive biomarker that informs treatment. The current definition of CD30 positivity by immunohistochemistry is descriptive and based on reactivity in lymphomas that are defined by their universal strong expression of CD30, rather than any established threshold. Challenges include inconsistencies with preanalytic variables, tissue processing, pathologist readout, and with the pathologist and oncologist interpretation of reported results.
To develop and propose general best practice recommendations for reporting CD30 expression by immunohistochemistry in lymphoma biopsies to harmonize practices across institutions and facilitate assessment of its significance in clinical decision-making.
Following literature review and group discussion, the panel of 14 academic hematopathologists and 2 clinical/academic hematologists/oncologists divided into 3 working groups. Each working group was tasked with assessing CD30 testing by immunohistochemistry, CD30 expression readout, or CD30 expression interpretation.
Panel recommendations were reviewed and discussed. An online survey was conducted to confirm the consensus recommendations.
CD30 immunohistochemistry is required for all patients in whom classic Hodgkin lymphoma and any lymphoma within the spectrum of peripheral T-cell lymphoma are differential diagnostic considerations. The panel reinforced and summarized that immunohistochemistry is the preferred methodology and any degree of CD30 expression should be reported. For diagnostic purposes, the interpretation of CD30 expression should follow published guidelines. To inform therapeutic decisions, report estimated percent positive expression in tumor cells (or total cells where applicable) and record descriptively if nontumor cells are positive.
Supplemental digital content is available for this article. See text for hyperlink.
Horwitz received research support from Affimed, Millennium/Takeda, and SeaGen and consults with SeaGen, Tubulis, and Takeda. Hsi received research support for Eli Lilly and Abbvie and is a consultant with Cytomx and Seattle Genetics. Jagadeesh received research funding from Seagen. Lisano is an employee and owns stock in Quigen Inc. Peker serves on the advisory board of Seattle Genetics. Vij serves on the advisory board for Seagen. Xu serves on the advisory board of Seattle Genetics. The other authors have no relevant financial interest in the products or companies described in this article.